Dual-Drug Delivery Via the Self-Assembled Conjugates of Choline-Functionalized Graft Copolymers
Overview
Affiliations
Graft copolymers based on a choline ionic liquid (IL), [2-(methacryloyloxy)ethyl]-trimethylammonium chloride (TMAMA), were obtained by atom transfer radical polymerization. The presence of chloride counterions in the trimethylammonium groups promoted anion exchange to introduce fusidate anions (FUS, 32−55 mol.%) as the pharmaceutical anions. Both the choline-based IL copolymers and their ionic drug-carrier conjugates (FUS systems as the first type, 26−208 nm) formed micellar structures (CMC = 0.011−0.025 mg/mL). The amphiphilic systems were advantageous for the encapsulation of rifampicin (RIF, 40−67 mol.%), a well-known antibiotic, resulting in single-drug (RIF systems as the second type, 40−95 nm) and dual-drug systems (FUS/RIF as the third type, 31−65 nm). The obtained systems released significant amounts of drugs (FUS > RIF), which could be adjusted by the content of ionic units and the length of the copolymer side chains. The dual-drug systems released 31−55% FUS (4.3−5.6 μg/mL) and 19−31% RIF (3.3−4.0 μg/mL), and these results were slightly lower than those for the single-drug systems, reaching 45−81% for FUS (3.8−8.2 μg/mL) and 20−37% for RIF (3.4−4.0 μg/mL). The designed polymer systems show potential as co-delivery systems for combined therapy against drug-resistant strains using two drugs in one formula instead of the separate delivery of two drugs.
Konieczkowska J, Neugebauer D, Kozanecka-Szmigiel A, Mazur A, Kotowicz S, Schab-Balcerzak E Sci Rep. 2024; 14(1):9078.
PMID: 38643277 PMC: 11032328. DOI: 10.1038/s41598-024-59704-1.
Niesyto K, Mazur A, Neugebauer D Pharmaceutics. 2024; 16(2).
PMID: 38399252 PMC: 10891911. DOI: 10.3390/pharmaceutics16020198.
Niesyto K, Keihankhadiv S, Mazur A, Mielanczyk A, Neugebauer D Int J Mol Sci. 2024; 25(2).
PMID: 38279291 PMC: 10816880. DOI: 10.3390/ijms25021292.
Mazur A, Neugebauer D Pharmaceutics. 2023; 15(11).
PMID: 38004535 PMC: 10674915. DOI: 10.3390/pharmaceutics15112556.
Keihankhadiv S, Neugebauer D Pharmaceuticals (Basel). 2023; 16(10).
PMID: 37895973 PMC: 10610373. DOI: 10.3390/ph16101502.